BioStem Technologies Acquires BioTissue's Surgical and Wound Care Business
January 22, 2026
BioStem Technologies (OTC: BSEM) has acquired the surgical and wound care business of BioTissue Holdings, Inc. for approximately $15 million upfront, with up to $25 million of contingent milestone and royalty payments. The deal includes the Neox and Clarix product lines, a nationwide commercial sales organization and assigned GPO contracts, expanding BioStem's access into hospital inpatient and outpatient wound-care markets and adding assets that generated roughly $29 million in 2025.
- Buyers
- BioStem Technologies, Inc.
- Targets
- BioTissue surgical and wound care business (BioTissue Holdings, Inc.)
- Sellers
- BioTissue Holdings, Inc.
- Industry
- Medical Devices
- Location
- Florida, United States
- Transaction Type
- Divestiture
Explore More
Related Acquisitions
-
Merit Medical Systems Acquires Biolife Delaware
May 28, 2025
Medical Devices
Merit Medical Systems has acquired Biolife Delaware, a Sarasota, Florida-based maker of StatSeal and WoundSeal hemostatic devices, in a cash transaction valued at approximately $120 million (including assumed liabilities). The deal expands Merit's hemostasis and wound-care product portfolio and is expected to modestly impact 2025 non-GAAP profitability while enhancing Merit's ability to serve a broad set of percutaneous procedure end markets.
-
EmergentMedTech Merges with TRU Biologix
January 22, 2025
Biotechnology
EmergentMedTech announced a merger with TRU Biologix to integrate TRU Biologix's Wharton's Jelly–derived cell and tissue biologics into EmergentMedTech's regenerative medicine and aesthetics product portfolio. The deal expands EmergentMedTech's capabilities alongside its role as the exclusive U.S. distributor of NeoGen PSR, enabling delivery of advanced biologics to hundreds of clinics and clinician partners.
-
Bioventus Inc. Acquires Misonix, Inc.
July 29, 2021
Medical Devices
Bioventus Inc. entered into a definitive agreement to acquire Misonix, Inc. in a cash-and-stock transaction that values Misonix at approximately $518 million on a fully diluted basis. The deal expands Bioventus' regenerative medicine and surgical solutions portfolio by adding Misonix's minimally invasive ultrasonic technologies and regenerative wound products and is expected to close in the fourth quarter of 2021 subject to customary approvals.
-
Solventum Acquires Acera Surgical
December 23, 2025
Medical Devices
Solventum (NYSE: SOLV) has completed the acquisition of Acera Surgical, a privately held bioscience company that develops synthetic tissue matrices for regenerative wound care, for $725 million upfront plus up to $125 million in contingent payments. The deal expands Solventum's MedSurg and advanced wound care portfolio with Acera's synthetic electrospun matrix technology; Acera is expected to generate about $90 million in sales in 2025.
-
Bioventus Acquires Bioness, Inc.
March 30, 2021
Medical Devices
Bioventus Inc. acquired Bioness, Inc. for $45 million in up-front consideration plus up to $65 million of contingent consideration, making Bioness a wholly‑owned subsidiary. The acquisition expands Bioventus' rehabilitation and neuromodulation product portfolio and R&D pipeline, and is expected to be accretive to revenue by leveraging Bioventus' global commercial infrastructure.
-
Medix Biochemica Group Acquires Bioresource Technology (BRT)
June 21, 2022
Biotechnology
Medix Biochemica has acquired a 100% stake in US-based Bioresource Technology (BRT) to expand its base matrix capabilities and strengthen its presence in the United States. BRT will be integrated into Medix Biochemica’s IVD Biomaterials Business Unit (St. Louis) while operations continue in Weston, Florida, and BRT leadership will serve as strategic advisors.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.